Dexcom Stock News

Dublin, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The "Diabetes Care Intelligence Center" report has been added to ResearchAndMarkets.com''s offering.

This past Friday two events spooked the diabetes device world. The first was news that Abbott filed an IP lawsuit against Dexcom, the second Insulet announced the OmniPod 5 approval would not come before the end of 2021 more likely sometime in the first quarter The post These things happen appeared first on Diabetic Investor .

NEXT Financial Group Inc boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 9.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 301 shares of the medical device companys stock after buying an additional 27 shares during the quarter. NEXT Financial Group Incs []

Edmonds Duncan Registered Investment Advisors LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 7.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 700 shares of the medical device companys stock after buying an additional 50 shares during the period. Edmonds Duncan Registered Investment Advisors LLCs []

Clarius Group LLC boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 9.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 537 shares of the medical device companys stock after acquiring an additional 46 shares during the period. Clarius Group LLCs holdings in []

LAS VEGAS , Dec. 1, 2021 /PRNewswire/ -- DelveInsight''s Insulin Delivery Devices Market Insights and Forecast report provides the current and forecast Insulin Delivery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Insulin Delivery Devices Market. Some of the salient features from the Insulin Delivery Devices Market report: As per DelveInsight analysis, in terms of revenue share, APAC is predicted to register the fastest growth in the Insulin Delivery Devices market because of the high prevalence of diabetes. Major pharma players working proactively in the Insulin Delivery Devices Market include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean ( Hangzhou ) Medical Technology Co Ltd, Owen Mumford , SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others.

DNB Asset Management AS increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 14,062 shares of the medical device companys stock after purchasing an additional 397 shares during the period. DNB Asset Management ASs holdings in DexCom were worth $7,690,000 as of []

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the 33rd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 1, 2021 at 2:30 PM (ET). The presentation will be concurrently webcast. The link to the webcast will be available on the Dexcom IR we

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference: Jereme Sylvain, Executive Vi

These businesses have been very efficient in generating profits Related Stocks: ZTS , DXCM , ZBRA , CNHI ,

When a company's return on equity (ROE) ratio is better than most of its competitors, it generally indicates that the company has been very efficient in generating profits. Thus, investors may want to

DexCom Inc. (NASDAQ:DXCM) shares, rose in value on Friday, 11/26/21, with the stock price down by -1.11% to the previous days close as strong demand from buyers drove the stock to $591.96. Actively observing the price movement in the last trading, the stock closed the session at $598.58, falling within a range of $589.45 and Is DexCom Inc. (NASDAQ: DXCM) A Good Pick For New Investors Now? Read More »

After a strong reaction to its last earnings report, we locked in gains because of these rules.

HNP Capital LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 3.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,895 shares of the medical device companys stock after acquiring an additional 122 shares during the period. HNP Capital LLCs holdings in DexCom []

Related Stocks: DXCM ,